Clinical Report: Communicating Geographic Atrophy Diagnosis and Treatment

Overview

Geographic atrophy (GA), the advanced form of dry age-related macular degeneration (AMD), leads to progressive central vision loss with an average onset around 2.5 years post-diagnosis. Recent approval of two intravitreal complement-targeting therapies offers hope by slowing GA progression, necessitating clear, compassionate patient communication about diagnosis and treatment options.

Background

GA is characterized by degeneration of the central retina, causing blind spots and visual distortions that worsen over time, impacting activities such as reading and driving. Historically, management was limited to lifestyle changes and low vision aids due to lack of specific treatments. The advent of novel intravitreal injections that slow disease progression marks a significant advancement, although these treatments do not reverse or halt GA entirely. Optometrists play a key role in educating patients to prepare them for specialist referral and informed decision-making.

Data Highlights

The average time from GA diagnosis to onset of central vision loss is approximately 2.5 years. Treatment involves ongoing intravitreal injections administered monthly or every other month. Most patients tolerate injections well, experiencing only transient pressure or mild eye irritation post-procedure.

Key Findings

• GA causes progressive central vision loss but spares peripheral vision, allowing many patients to maintain independence with low vision support.
• Early symptoms include difficulty with night driving, poor illumination, and reading fine print; later symptoms include visual distortions and blind spots.
• Two new intravitreal medications targeting the complement system have been approved to slow GA progression but do not improve or stop vision loss.
• Treatment requires long-term, repeated eye injections, generally well tolerated with minimal discomfort.
• Effective patient communication using clear language and visual aids like fundus autofluorescence imaging improves understanding and reduces anxiety.
• Optometrists are essential in educating patients about GA and treatment options to facilitate informed decisions and smooth specialist referrals.

Clinical Implications

Clinicians should approach GA diagnosis discussions with empathy and clarity, emphasizing that while vision loss will likely continue, treatment can slow progression and extend functional vision. Using visual tools and plain language helps patients grasp their condition and treatment expectations. Preparing patients for the injection process and potential side effects can reduce anxiety and improve treatment adherence.

Conclusion

The emergence of treatments for GA transforms patient management, making clear, compassionate communication vital. Empowering patients with knowledge fosters confidence and supports shared decision-making in their care journey.

References

1. Haynes J. 2024 -- Talking to Patients About Geographic Atrophy